Gefitinib treatment affects androgen levels in non-small-cell lung cancer patients

Gefitinib, an inhibitor of the epidermal growth factor receptor (EGFR, HER1/ErbB1) tyrosine kinase, has been shown to have clinical activity against non-small-cell lung cancers (NSCLCs), especially in women nonsmokers with adenocarcinomas. The aim of the present study was to clarify the relationship...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishio, M, Ohyanagi, F, Horiike, A, Ishikawa, Y, Satoh, Y, Okumura, S, Nakagawa, K, Nishio, K, Horai, T
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361759/
https://www.ncbi.nlm.nih.gov/pubmed/15870715
http://dx.doi.org/10.1038/sj.bjc.6602585

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361759/
https://www.ncbi.nlm.nih.gov/pubmed/15870715
http://dx.doi.org/10.1038/sj.bjc.6602585

Ejemplares similares